Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome

Brian C. Shaffer, Martin Tallman, Adriana K. Malone, Ran Reshef, Mark Litzow, Jane Liesveld, Peter H. Wiernik, Kwang Woo Ahn, Zhen Huan Hu, Wael Saber, Taiga Nishihori, Mohamed A. Kharfan-Dabaja, David Valcárcel, Michael R. Grunwald, Omotayo Fasan, Edward Copelan, William Allen Wood, David A. Rizzieri, Ulrike Bacher, Betty HamiltonAaron Gerds, Matt Kalaycio, Ron Sobecks, Basem William, Ayman Saad, Luciano J. Costa, Corey Cutler, Edwin Alyea, Erica Warlick, Celalettin Ustun, Baldeep Mona Wirk, Mitchell Sabloff, Andrew Daly, David Marks, Robert Peter Gale, Richard Olsson, Alan M. Miller, Rammurti Kamble, Jorge Cortes, Uday Popat, Tamila L. Kindwall-Keller, Jean Yves Cahn, Bipin N. Savani, Ravi Vij, Richard Maziarz, Steven Pavletic

Research output: Contribution to journalArticlepeer-review

55 Scopus citations


Purpose To develop a system prognostic of outcome in those undergoing allogeneic hematopoietic cell transplantation (allo HCT) for myelodysplastic syndrome (MDS). Patients and Methods We examined 2,133 patients with MDS undergoing HLA-matched (n = 1,728) or -mismatched (n = 405) allo HCT from 2000 to 2012. We used a Cox multivariable model to identify factors prognostic of mortality in a training subset (n = 1,151) of the HLA-matched cohort. A weighted score using these factors was assigned to the remaining patients undergoing HLA-matched allo HCT (validation cohort; n = 577) as well as to patients undergoing HLA-mismatched allo HCT. Results Blood blasts greater than 3% (hazard ratio [HR], 1.41; 95% CI, 1.08 to 1.85), platelets 50 3 109 /L or less at transplantation (HR, 1.37; 95% CI, 1.18 to 1.61), Karnofsky performance status less than 90% (HR, 1.25; 95% CI, 1.06 to 1.28), comprehensive cytogenetic risk score of poor or very poor (HR, 1.43; 95% CI, 1.14 to 1.80), and age 30 to 49 years (HR, 1.60; 95% CI, 1.09 to 2.35) were associated with increased hazard of death and assigned 1 point in the scoring system. Monosomal karyotype (HR, 2.01; 95% CI, 1.65 to 2.45) and age 50 years or older (HR, 1.93; 95% CI, 1.36 to 2.83) were assigned 2 points. The 3-year overall survival after transplantation in patients with low (0 to 1 points), intermediate (2 to 3), high (4 to 5) and very high ([[ampi]]ge; 6) scores was 71% (95% CI, 58% to 85%), 49% (95% CI, 42% to 56%), 41% (95% CI, 31% to 51%), and 25% (95% CI, 4% to 46%), respectively (P [[ampi]]lt; .001). Increasing score was predictive of increased relapse (P , .001) and treatment-related mortality (P [[ampi]]lt; .001) in the HLA-matched set and relapse (P [[ampi]]lt; .001) in the HLA-mismatched cohort. Conclusion The proposed system is prognostic of outcome in patients undergoing HLA-matched and -mismatched allo HCT for MDS.

Original languageEnglish (US)
Pages (from-to)1864-1871
Number of pages8
JournalJournal of Clinical Oncology
Issue number16
StatePublished - Jun 1 2016

Bibliographical note

Funding Information:
The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two Grants, N00014-06-1-0704 and N00014-08-1-0058, from the Office of Naval Research; and grants from Allos, Inc.; Amgen, Inc.; Angioblast; an anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children's Leukemia Research Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; Kiadis Pharma; The Leukemia and Lymphoma Society; The Medical College of Wisconsin; Millennium Pharmaceuticals, Inc.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Optum Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; Swedish Orphan Biovitrum; THERAKOS, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, or any other agency of the U.S. Government.

Publisher Copyright:
© 2016 by American Society of Clinical Oncology.


Dive into the research topics of 'Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome'. Together they form a unique fingerprint.

Cite this